These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12358947)

  • 1. The use of recombinant factor viia in a jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage.
    Waddington DP; McAuley FT; Hanley JP; Summerfield GP
    Br J Haematol; 2002 Oct; 119(1):286-8. PubMed ID: 12358947
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe gastrointestinal haemorrhage responding to recombinant factor VIIa in a Jehovah's Witness with refractory immune thrombocytopenia.
    Virchis A; Hughes C; Berney S
    Hematol J; 2004; 5(3):281-2. PubMed ID: 15167918
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven).
    Tanaka KA; Waly AA; Cooper WA; Levy JH
    Anesthesiology; 2003 Jun; 98(6):1513-5. PubMed ID: 12766668
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinant factor VIIa for major obstetric haemorrhage in a Jehovah's Witness.
    Laird R; Carabine U
    Int J Obstet Anesth; 2008 Apr; 17(2):193-4. PubMed ID: 18308545
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of recombinant activated factor VII in a Jehovah's Witness patient.
    Hsieh A; Cheong I
    Am J Emerg Med; 2007 Nov; 25(9):1085.e1-2. PubMed ID: 18022514
    [No Abstract]   [Full Text] [Related]  

  • 6. Preferences of Jehovah's Witnesses regarding haematological supports in an obstetric setting: experience of a single university teaching hospital.
    Husarova V; Donnelly G; Doolan A; Garstka M; Ni Ainle F; McCaul C
    Int J Obstet Anesth; 2016 Feb; 25():53-7. PubMed ID: 26597403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splenic embolization in a Jehovah's Witness: role of recombinant human factor VIIa.
    Mindikoglu AL; Anantharaju A; George M; Leone N; Bejna J; Van Thiel DH
    Hepatogastroenterology; 2003; 50(53):1697-9. PubMed ID: 14571820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality risk stratification in severely anaemic Jehovah's Witness patients.
    Beliaev AM; Marshall RJ; Smith W; Windsor JA
    Intern Med J; 2012 Mar; 42(3):e1-3. PubMed ID: 22432994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postpartum hemorrhage in a Jehovah's Witness patient controlled with Tisseel, tranexamic acid, and recombinant factor VIIa.
    Arab TS; Al-Wazzan AB; Maslow K
    J Obstet Gynaecol Can; 2010 Oct; 32(10):984-7. PubMed ID: 21176309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of intestinal hemorrhage in a Jehovah's Witness patient.
    Veneri D; Franchini M
    Am J Hematol; 2005 Aug; 79(4):344-5. PubMed ID: 16044447
    [No Abstract]   [Full Text] [Related]  

  • 11. Is total hip arthroplasty a successful and safe procedure in Jehovah's Witnesses? Mean five-year results.
    Harwin SF; Pivec R; Naziri Q; Issa K; Mont MA
    Hip Int; 2014; 24(1):69-76. PubMed ID: 24318363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human coagulation factor VIIa in Jehovah's Witness patients undergoing liver transplantation.
    Jabbour N; Gagandeep S; Peilin AC; Boland B; Mateo R; Genyk Y; Selby R; Zeger G
    Am Surg; 2005 Feb; 71(2):175-9. PubMed ID: 16022020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa.
    Sniecinski RM; Chen EP; Levy JH; Szlam F; Tanaka KA
    Anesth Analg; 2007 Apr; 104(4):763-5. PubMed ID: 17377078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aortic dissection and hypothermic arrest in a Jehovah's Witness patient: a case for recombinant factor VIIa?
    Ballen J; Raabe M; Muirhead B
    Can J Anaesth; 2006 Apr; 53(4):353-6. PubMed ID: 16575032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of recombinant activated factor VII for reduction of perioperative blood loss during elective surgical correction of spine deformity in a Jehovah's Witness. Case report.
    Kącka K; Kącki W; Merak J; Błęka A
    Ortop Traumatol Rehabil; 2010; 12(5):448-58. PubMed ID: 21057153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttonsillectomy Hemorrhage in a Pediatric Jehovah's Witness and the Decision to Transfuse.
    Redmann AJ; Schopper M; Ragsdale J; Rutter MJ; Hart CK; Myer CM
    Otolaryngol Head Neck Surg; 2018 Aug; 159(2):238-241. PubMed ID: 29807476
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding.
    Kandane-Rathnayake RK; Isbister JP; Zatta AJ; Aoki NJ; Cameron P; Phillips LE;
    ANZ J Surg; 2013 Mar; 83(3):155-60. PubMed ID: 23035873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An audit of gynaecological procedures in Jehovah's Witnesses in an inner city hospital.
    Massiah N; Abdelmagied A; Samuels D; Evans F; Okolo S; Yoong W
    J Obstet Gynaecol; 2006 Feb; 26(2):149-51. PubMed ID: 16483975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contemporary approach to the care of Jehovah's witnesses.
    Hughes DB; Ullery BW; Barie PS
    J Trauma; 2008 Jul; 65(1):237-47. PubMed ID: 18580506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful management of thrombotic thrombocytopenic purpura in a Jehovah's Witness without plasma exchange.
    Chai W; Chaudhry A; Rabinowitz AP
    J Clin Apher; 2015 Feb; 30(1):46-9. PubMed ID: 24782109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.